Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00606645 · ClinicalTrials.gov registry record · Phase 1
Safety Study of XmAb®2513 to Treat Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma
A Phase 1 study of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma, sponsored by Xencor.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
- 4
- Study locations
NCT00606645: Completed Phase 1 study of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma, sponsored by Xencor.
NCT00606645 is a Phase 1 study of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma that has completed, run by Xencor. The registered enrollment target is 23 participants, below the 166-participant average among 71 other Hodgkin Lymphoma trials with a reported enrollment target (86% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00606645, a Phase 1 study of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma, has completed, sponsored by Xencor.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
- 4
- Study locations
Study Summary
An open-label, multi-dose, single-arm, Phase 1 dose escalation study of XmAb®2513 was conducted to define the MTD or recommended dose(s) for further study, to determine safety and tolerability, to characterize PK and immunogenicity, and to evaluate antitumor activity of XmAb2513 in patients with HL and ALCL (non-cutaneous) and who have received two or more prior therapeutic regimens. There will be no intra-patient dose escalation.
Conditions Studied
Interventions
- BIOLOGICAL XmAb2513
Study Locations (4)
Illinois
- Rush University Medical Center - Chicago
Ohio
- Ohio State University - Columbus
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2007-12 |
| Est. Completion | 2010-04 |
| Phase | Phase 1 |
What the finished NCT00606645 record still lists
NCT00606645 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 166-participant average among 71 other Hodgkin Lymphoma trials with a reported enrollment target (86% lower).
The record links to 2 conditions, with Hodgkin Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which XmAb2513 is the first listed.
NCT00606645 reports a single indexed study location in Illinois, Ohio, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00606645 about?
NCT00606645 is a clinical study titled "Safety Study of XmAb®2513 to Treat Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma". An open-label, multi-dose, single-arm, Phase 1 dose escalation study of XmAb®2513 was conducted to define the MTD or recommended dose(s) for further study, to determine safety and tolerability, to characterize PK and immunogenicity, and to evaluate antitumor activity of XmAb2513 in patients with HL ...
What is the current status of trial NCT00606645?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2007-12. Estimated completion is 2010-04.
What conditions does trial NCT00606645 study?
This clinical trial studies the following conditions: Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma.
What interventions are being tested in trial NCT00606645?
The interventions under investigation include: XmAb2513 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00606645?
This trial is sponsored by Xencor, which has 27 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00606645 being conducted?
This trial has 4 study locations across Illinois, Ohio, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00606645's enrollment target sits among peer trials
23 56th of 71 higher than 16 of 71 other Hodgkin Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hodgkin Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
RECRUITING · Phase 1
-
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
RECRUITING · Phase 1
-
Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma
RECRUITING · Phase 1
-
AZD3470 as Monotherapy and in Combination With Anticancer Agents in Participants With Relapsed/Refractory Haematologic Malignancies.
RECRUITING · Phase 1
-
ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells
RECRUITING · Phase 1
-
Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia